Ranbaxy Laboratories has signed an exclusive in-licencing agreement with Sirtex Medical, Australia, to promote and market Sirtex's SIR-Spheres. The product, approved by the US Food and Drug Authority, is used for the treatment of patients with inoperable tumors from primary colorectal cancer that have spread to the liver. Sanjeev Dani, senior vice president & regional director, Asia & CIS, Ranbaxy, said, "We are pleased to partner Sirtex for this unique, high technology product. We shall work towards creating a productive relationship by complementing each others' strengths. The agreement will enable Ranbaxy to further strengthen our position in the oncology segment." SIR-Spheres has been used to treat liver cancer patients in Australia, USA, Europe, New Zealand and Asia in a variety of clinical trials and general practice. |